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Voltage-gated potassium (Kv) channels are critical in controlling neuronal excitability and are involved in the induction
of neuropathic pain. Therefore, Kv channels might be potential targets for prevention and/or treatment of this disorder.
We reported here that a majority of dorsal root ganglion (DRG) neurons were positive for Kv channel alpha subunit
Kv1.2. Most of them were large and medium, although there was a variety of sizes. Peripheral nerve injury caused by
lumbar (L)5 spinal nerve ligation (SNL) produced a time-dependent reduction in the number of Kv1.2-positive neurons
in the ipsilateral L5 DRG, but not in the contralateral L5 DRG. Such reduction was also observed in the ipsilateral L5 DRG
on day 7 after sciatic nerve axotomy. Rescuing nerve injury-induced reduction of Kv1.2 in the injured L5 DRG attenuated
the development and maintenance of SNL-induced pain hypersensitivity without affecting acute pain and locomotor
function. This effect might be attributed to the prevention of SNL-induced upregulation of endogenous Kv1.2 antisense
RNA, in addition to the increase in Kv1.2 protein expression, in the injured DRG. Our findings suggest that Kv1.2 may be
a novel potential target for preventing and/or treating neuropathic pain.
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Peripheral nerve injury often causes persistent neuro-
pathic pain that is characterized by spontaneous ongoing
or intermittent burning pain, allodynia, and hyperalgesia
[1]. Treatment options are limited in part because our un-
derstanding of the mechanisms that underlie the induc-
tion and maintenance of neuropathic pain is incomplete
[2,3]. Peripheral nerve injury causes several changes in the
nervous system, including abnormal ectopic firing from
neuromas and dorsal root ganglion (DRG) neurons [1,4,5].
These abnormal neuronal activities play a critical role in
the development and maintenance of neuropathic pain.* Correspondence: yt211@njms.rutgers.edu
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stated.DRG neurons express a variety of ion channels, in-
cluding voltage-gated potassium (Kv) channels [6-8]. Kv
channels are tetramers of superfamily-specific channel
subunits that comprise ion-conducting integral protein α
subunits and auxiliary cytoplasmic β subunits. More
than a dozen α subunits of the Kv channel have been
isolated from mammalian cells and divided into 12 sub-
families, Kv1–12; many subfamilies consist of more than
one subunit [9,10]. Because Kv channels are critical for
establishing resting membrane potential and controlling
neuronal excitability [11], changes in the expression
levels and operating characteristics of Kv channels in the
DRG after peripheral nerve injury may contribute to ab-
normal activities of DRG neurons in neuropathic pain.
The Kv1.2 subunit may participate in the formation of
Kv channel tetramers in most DRG neurons. The mRNA
for Kv1.1 and Kv1.2 is highly abundant, whereas that of
Kv1.3, Kv1.4, Kv1.5, and Kv1.6 is present at lower levels
in the DRG [12]. Some controversy exists regarding the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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example, Ishikawa et al. [13] showed that Kv1.2 was
expressed in small DRG neurons, whereas Rasband et al.
[14] revealed that Kv1.2 was predominantly distributed in
large DRG neurons. Interestingly, peripheral nerve injury
down-regulated the expression of Kv1.2 in the injured
DRG [12-15]. This down-regulation may be responsible
for the nerve injury-induced increase in the ectopic dis-
charge activity observed in DRG neurons [16]. Therefore,
DRG Kv.1.2 might be a potential target for neuropathic
pain treatment.
In the present study, we first characterized the sub-
population distribution patterns and neurochemical
properties of Kv1.2-positive cells. Second, we used im-
munohistochemistry to further examine the temporal
change in the number of K v1.2-positive neurons in the
injured DRG in two peripheral nerve injury models:
lumbar (L)5 spinal nerve ligation (SNL) and sciatic
nerve transection (axotomy). Finally, we tested whether
rescuing Kv1.2 downregulation by over-expressing
Kv1.2 RNA in the injured DRG affected SNL-induced
neuropathic pain, acute pain, and locomotor functions.Materials and methods
Animals
Male Sprague–Dawley rats (250–300 g, Harlan Biopro-
ducts for Science, Indianapolis, IN) were housed in cages
on a standard 12:12 h light/dark cycle. Water and food
were available ad libitum until rats were transported to
the laboratory approximately 1 h before experiments. All
experimental procedures received prior approval from the
Animal Care and Use Committee at the Johns Hopkins
University. Animal procedures were consistent with the
ethical guidelines of the National Institutes of Health and
the International Association for the Study of Pain and
the ethical guidelines to investigate experimental pain in a
conscious animal. Efforts were made to minimize animal
suffering and to reduce the number of animals used. The
experimenters were blind to the treatment condition du-
ring the behavioral testing.DRG microinjection
DRG microinjection was carried out as described
[17-19]. Briefly, the DRG was exposed by laminectomy.
A midline incision was made in the lower lumbar back
region, and the L5 vertebral body was exposed. The la-
mina was then removed with small ronguers. After the
DRG was exposed, viral solution (2 μl/DRG, 1012 parti-
cles/ml) was injected into one site in the L5 DRG with a
glass micropipette connected to a Hamilton syringe. The
pipette was removed 10 min after injection. The surgical
field was irrigated with sterile saline and the skin inci-
sion closed with wound clips.L5 SNL-induced neuropathic pain model
L5 SNL was carried out according to our previous proto-
cols [20-23]. Briefly, after the rats were anesthetized with
isoflurane, the left L6 transverse process was removed to
expose the L4 and L5 spinal nerves. The L5 spinal nerve
was then carefully isolated, tightly ligated with 3–0 silk
thread, and transected just distal to the ligature. The
surgical procedure for the sham group was identical to
that of the SNL group, except that the spinal nerve was
not transected or ligated.
Sciatic nerve axotomy
After the rats were anesthetized with isoflurane, the left
sciatic nerve was exposed, and the nerve was cut at a
point approximately 1 cm distal to the exit point of
spinal nerve roots according to the method described
previously [20]. Proximal and distal stumps were sepa-
rated to ensure full transection. In the sham group, the
surgical procedure was identical, except that the sciatic
nerve was not transected.
Capsaicin-induced acute pain
The experimental procedure used for the capsaicin test
was carried out as described previously [24]. Briefly, fifty
μl of vehicle (0.7% alcohol) or capsaicin (2 μg) was
injected intradermally under the dorsal surface of the rat
left hindpaw by use of a microsyringe with a 26-gauge
needle. The amount of time that animals spent licking
and/or lifting the injected paw was measured with a
stopwatch and was considered as an indicator of the
nocifensive response. The animal was observed indi-
vidually for 5 min immediately after the injection of
vehicle or capsaicin. Mechanical, cold, and thermal tests
as described below were carried out 30 min after the in-
jection of vehicle or capsaicin.
Behavioral testing
Mechanical paw withdrawal thresholds were measured
with the up–down testing paradigm 1 day before surgery
and on days 3, 7, and 14 after SNL or sham surgery
according to our previous reports [20-22]. Briefly, the
rat was placed in a Plexiglas chamber on an elevated
mesh screen. Von Frey hairs in log increments of force
(0.407, 0.692, 1.202, 2.041, 3.63, 5.495, 8.511, 15.14 g)
were applied to the plantar surface of the left and right
hind paws. The 2.041-g stimulus was applied first. If a
positive response occurred, the next smaller von Frey
hair was used; if a negative response was observed, the
next higher von Frey hair was used. The test was ended
when (i) a negative response was obtained with the
15.14-g hair, (ii) four stimuli were applied after the first
positive response, or (iii) nine stimuli were applied to
one hind paw.
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a cold plate, the temperature of which was monitored
continuously. A differential thermocouple thermometer
(Harvard Apparatus, South Natick, MA) attached to the
plate provided temperature precision of 0.1°C. Each ani-
mal was placed in a Plexiglas chamber on the cold plate,
which was set at 0°C. The length of time between the
placement of the hind paw on the plate and the animal
jumping, with or without paw licking and flinching, was
defined as the paw withdrawal latency. Each trial was
repeated three times at 10-min intervals for the paw on
the ipsilateral side. A cutoff time of 60 s was used to
avoid paw tissue damage.
Paw withdrawal latencies to heat were measured with
a Model 336 Analgesia Meter (IITC Life Science Instru-
ments, Woodland Hills, CA, USA). Each animal was
placed in a Plexiglas chamber on a glass plate (at 25°C)
located above a light box. Radiant heat was applied by
aiming a beam of light through a hole in the light box
through the glass plate to the middle of the plantar sur-
face of each hind paw. When the animal lifts its paw in
response to the heat, the light beam is turned off. The
length of time between the start of the light beam and
the foot lift was defined as the paw withdrawal latency.
Each trial was repeated five times at 5-minute intervals
for each paw. A cutoff time of 20 seconds was used to
avoid paw tissue damage.
The following locomotor function tests were per-
formed: (1) Placing reflex: The rat was held with the
hind limbs slightly lower than the forelimbs, and the
dorsal surfaces of the hind paws were brought into con-
tact with the edge of a table. The experimenter recorded
whether the hind paws were placed on the table surface
reflexively; (2) Grasping reflex: The rat was placed on a
wire grid and the experimenter recorded whether the
hind paws grasped the wire on contact; (3) Righting re-
flex: The rat was placed on its back on a flat surface and
the experimenter noted whether it immediately assumed
the normal upright position. Scores for placing, grasping,
and righting reflexes were based on counts of each nor-
mal reflex exhibited in five trials.
Plasmid construction, cell culture and transfection, and
virus production
To construct the full-length Kv1.2 expression plasmid,
total RNA was extracted from rat DRG tissue using Trizol.
The reverse transcription was performed with specific pri-
mer (5′-GGGTGACTCTCATCTTTGGA-3′). Then the
full-length sequence of Kv1.2 cDNA was amplified using
primers (Forward: 5′-ATCCACCGGTGCCACCATGA
CAGTGGCTACC GGAGA-3′; Reverse: 3′-ATAGTT
TAGCGGCCGCTCAGACATCAGTTAACATTTTGG-5′).
The PCR products were subsequently digested using AgeI
and NotI and cloned into the restriction sites of theproviral plasmids (pHpa-trs-SK, provided by Dr. R.J.
Samulski, University of North Carolina, Chapel Hill) to
replace enhanced GFP (EGFP) sequence. The cDNA
sequence and recombinant clones were verified by using
DNA sequencing. The resulting two vectors expressed
EGFP and Kv1.2 RNA under the control of the cyto-
megalovirus promoter. AAV5 viral particles carrying the
two cDNAs were produced at the University of North
Carolina Vector Core.
Human embryonic kidney 293 (HEK293) cells (1 × 106)
were seeded in 6-well culture plates and cultured in
Dulbecco’s modified Eagle medium supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin so-
lution (10,000 U/ml and 10 mg/ml, respectively). After 24
hours of culture, 2.5 μg of the plasmids (pHpa-trs-Kv1.2
or pHpa-trs-EGFP) were transfected into the HEK-293 T
cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. After the
4-day incubation, the cells were collected and subjected to
Western blot analysis as described below.
Total RNA preparation and quantitative real-time RT-PCR
RNA extraction and real-time RT-PCR were performed ac-
cording to our previously published protocols [20,21].
Briefly, rats were decapitated, and bilateral L4/5 DRGs and
L5 spinal cord were rapidly collected. To obtain enough
RNA, L4 or L5 DRGs from one side of three rats per time
point were pooled. Total RNA was extracted with the Tri-
zol method (Invitrogen, Carlsbad, CA), precipitated with
isopropanol, treated with RNase-free DNase I (1 μL/20 μL;
Promega Corp., Madison, WI), and reverse-transcribed by
using the Omniscript kit (Qiagen, Valencia, CA) with
specific primers [Kv1.2: 5′-GGG TGA CTC TCA TCT
TTG GA-3′, Kv1.2 AS: 5′-CGTCACACCTCCTGAG
GACAG-3′, or glyceraldehyde-3-phosphate dehydro-
genase (GAPDH, an internal control for normalization):
5′-GAG CAC AGG GTA CTT TAT TGA T -3′]. cDNA
was amplified by real-time PCR by using the probes for
Kv1.2/Kv1.2 AS (5′-/56-FAM/TGC TGT TGG AAT
AGG TGT GGA AGG T/BHQ_1/-3′) (Integrated DNA
Technologies, Coralville, IA), and GAPDH [probe/
primers were obtained from Applied Biosystems (cata-
log number: 4331182), Foster City, CA]. The Kv1.2 PCR
primer sequences were 5′-AGA AAG GGT CGG TGA
AGG AGG T-3′ (forward) and 5′-GTG TGG CTT CTC
TTT GAA TAC C-3′ (reverse). Kv1.2 AS PCR primer
sequence were 5′-GTG TGG CTT CTC TTT GAA
TAC C-3′ (forward) and 5′-AGA AAG GGT CGG TGA
AGG AGG T-3′ (reverse). Real-time PCR for each sam-
ple was run in quadruplicate in a 20-μL reaction with
TaqMan Universal PCR Master Mix (Applied Biosys-
tems). Reactions were performed in an ABI 7500 Fast
Real-Time PCR System (Applied Biosystems). The amp-
lification protocol was: 3 min at 95°C, followed by 45
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for annealing and extension. Ratios of ipsilateral-side
mRNA levels to contralateral-side mRNA levels were
calculated by using the ΔCt method (2−ΔΔCt) at a thresh-
old of 0.02. All data were normalized to GAPDH, which
has been demonstrated to be stable even during peri-
pheral nerve injury [20,21,25].
Western blot analysis
The protocol for Western blot analysis has been described
previously [26,27]. In brief, cultured cells and bilateral L5
DRGs were collected and rapidly frozen in liquid nitrogen.
The cultured cells were sonicated and tissues homo-
genized in chilled lysis buffer (50 mM Tris, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM EDTA, 1 μM leupeptin).
The crude homogenate was centrifuged at 4°C for 15 min
at 1,000 × g. The supernatant was collected and the pellet
(nuclei and debris fraction) discarded. After protein con-
centration was measured, the samples were heated at 99°C
for 5 min and loaded onto a 4% stacking/7.5% separat-
ing SDS-polyacrylamide gel (Bio-Rad Laboratories,
Hercules, CA). The proteins were then electrophore-
tically transferred onto a polyvinylidene difluoride
membrane (Immobilon-P, Millipore, Billerica, MA). The
membranes were blocked with 3% nonfat milk in Tris-
buffered saline containing 0.1% Tween-20 for 1 h and
incubated with primary mouse anti-Kv1.2 (NeuroMab,
Davis, CA), primary mouse anti-Kv1.4 (NeuroMab), or
primary mouse anti-β-actin (Santa-Cruz Biotechnology,
Santa Cruz, CA) overnight under gentle agitation. β-actin
was used as a loading control. The proteins were detected
by horseradish peroxidase-conjugated anti-mouse secon-
dary antibody and visualized by chemiluminescence re-
gents (ECL; Amersham Pharmacia Biotech, Piscataway,
NJ) and exposure to film. The intensity of blots was quan-
tified with densitometry. The blot density from the contra-
lateral side of the EGFP-treated group was set as 100%.
The relative density values from the ipsilateral side of the
EGFP group and the ipsilateral and contralateral sides of
Kv1.2-treated groups after sham or SNL were determined
by dividing the optical density values from these groups
by the value of the contralateral side in the EGFP-treated
group after they were normalized to the corresponding
β-actin.
Immunohistochemistry
After being deeply anesthetized with isoflurane, the rats
were perfused through the ascending aorta with 100 mL
of 0.01 M phosphate-buffered saline (PBS, pH 7.4)
followed by 400 mL of 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4). L5 DRGs were removed,
post-fixed in the same fixative for 2–4 h, and then cryo-
protected in 30% sucrose in 0.1 M phosphate buffer
overnight at 4°C. Transverse sections (20 μm thickness)were cut on a cryostat. For single labeling, every fourth
section was collected (at least 3–4 sections/DRG). For
double labeling, five sets of sections (2–3 sections/set)
were collected from each DRG by grouping every fifth
serial section.
Single-label immunofluorescence histochemistry was
carried out as described previously [28,29]. After being
blocked for 1 h at 37°C in PBS containing 10% goat
serum and 0.3% TritonX-100, the sections were incu-
bated alone with primary mouse monoclonal anti-Kv1.2
overnight at 4°C. The sections were then incubated
with goat anti-mouse IgG conjugated with Cy2 (1:400,
Jackson ImmunoResearch, West Grove, PA) for 2 h at
room temperature. Control experiments included sub-
stitution of normal mouse serum for the primary anti-
serum and omission of the primary antiserum. Finally,
the sections were rinsed in 0.01 M PBS and mounted
onto gelatin-coated glass slides. Cover slips were applied
with a mixture of 50% glycerin and 2.5% triethylene
diamine in 0.01 M PBS.
Double-label immunofluorescence histochemistry was
carried out as described previously [28,29]. Five sets of
sections were incubated overnight at 4°C with primary
mouse monoclonal anti-Kv1.2 and one each of the follo-
wing primary antibodies: rabbit anti-NF200 (Sigma, St.
Louis, MO), rabbit anti-P2X3 (Neuromics, Edina, MN),
biotinylated IB4 (1:100, Sigma), rabbit anti- substance P
(SP; Millipore), and rabbit anti- calcitonin gene-related
peptide (CGRP; EMD, Gibbstown, NJ). The sections were
then incubated for 1 h at 37°C with a mixture of goat anti-
mouse IgG conjugated with Cy3 (1:400, Jackson Immu-
noResearch) and donkey anti-rabbit IgG conjugated with
Cy2 (1:400, Jackson ImmunoResearch) or with a mixture
of goat anti-mouse IgG conjugated with Cy3 (1:400) and
FITC-labeled avidin D (1:200, Sigma) for 1 h at 37°C.
Control experiments as described above were performed
in parallel. After the sections were rinsed in 0.01 M PBS,
cover slips were applied as described above.
All immunofluorescence-labeled images were examined
under a Nikon TE2000E fluorescence microscope (Nikon
Co., Japan) and captured with a CCD spot camera. For
single labeling, all labeled and unlabeled neurons with nu-
clei were counted. Cell profiles were outlined and cell area
was calculated by using the imaging software Image-Pro
Plus (Media Cybernetics, Silver Spring, MD). For double
labeling, single-labeled and double-labeled neurons with
nuclei were counted.
Whole-cell patch clamp recording
Kv1.2 current was recorded in HEK293 cells transfected
with Kv1.2 or EGFP plasmid by using whole-cell patch
clamp recording 3–4 days after transfection. Cover slips
were placed into the perfusion chamber (Warner Instru-
ments, Hamden, CT) positioned on the stage of a
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borosilicate glass with a micropipette puller (PP-830,
Narishige, Japan), and the electrode resistances ranged
from 2 to 4 MΩ. Cells were voltage-clamped via the
whole-cell configuration of the patch clamp with an
Axopatch-700B amplifier (Molecular Devices, Sunnyvale,
CA). The intracellular pipette solution (ICS) contained
(in mM): potassium gluconate 120, KCl 20, MgCl2 2,
EGTA 10, HEPES 10, Mg-ATP 4 (pH = 7.3 with KOH,
310 mOsm). We minimized the Na+ and Ca2+ component
in Kv current recording by using an extracellular solution
composed of (in mM): choline-Cl 150, KCl 5, CdCl2 1,
CaCl2 2, MgCl2 1, HEPES 10, glucose 10 (pH = 7.4 with
Tris-base, 320 mOsm). Signals were filtered at 1 kHz
and digitized by using a DigiData 1322A with pClampFigure 1 Kv1.2 expression predominantly in the large and medium D
immunohistochemical staining showing the distribution of Kv1.2-positive n
Kv1.2-positive somata.9.2 software (Molecular Devices). Series resistance was
compensated by 60–80%. Cell membrane capacitances
were acquired by reading the value for whole-cell capa-
citance compensation directly from the amplifier. An
online P/4 leak subtraction was performed to eliminate
leak current contribution. The data were stored on
computer by a DigiData 1322A interface and were ana-
lyzed by the pCLAMP 9.2 software package (Molecular
Devices).
Statistical analysis
The results from the behavioral tests, Western blot, and
immunohistochemistry were statistically analyzed with a
one-way or two-way analysis of variance (ANOVA). Data
are presented as means ± SEM. When ANOVA showedRG neurons of normal rats. (A) A representative image from
eurons. Scale bar: 200 μm. (B) Histogram showing the distribution of
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means were tested by the post hoc Tukey method. Sig-
nificance was set at p < 0.05. The statistical software
package SigmaStat (Systat, San Jose, CA) or GraphPad
Prism 4.0 (GraphPad Software Inc., La Jolla, CA) was
used to perform all statistical analyses.
Results
Distribution of Kv1.2-positive neurons in DRG
Consistent with previous reports [14], a majority (70%)
of the DRG neurons are positive for Kv1.2 (Figure 1).
Most of these positive neurons are medium and large in
size. To further identify the cytochemical characteristics
of Kv1.2-labeled neurons in the L5 DRG, we carried out
double labeling immunohistochemistry for Kv1.2 and
neuronal subtype markers (n = 5 rats). In neuron pro-
files, approximately 80.3 ± 3.3% of Kv1.2-labeled neurons
were positive for NF200 (a marker for large cells and
myelinated A-fibers; Figure 2), whereas approximately
11.11 ± 2.18% of Kv1.2-labeled neurons were positive forFigure 2 Co-localization of Kv1.2 with NF200, IB4, P2X3, SP, and CGRP
approximately 80.3% of Kv1.2-labeled neurons are positive for NF200 (A–C)
10.7% for CGRP (M–O). Arrows: double-labeled neurons. Scale bar: 70 μm.P2X3 (a marker for small DRG non-peptidergic neurons,
Figure 2) and 10.7 ± 1.69% were positive for CGRP
(a marker for small DRG peptidergic neurons; Figure 2).
Interestingly, about 2.45 ± 1.31% of Kv1.2-labeled neu-
rons were positive for IB4 (another marker for small
DRG non-peptidergic neurons; Figure 2) and 3.97 ±
1.22% were positive for SP (another marker for small
DRG peptidergic neurons; Figure 2).
Reduction in number of Kv1.2-positive neurons in the
injured DRGs after peripheral nerve injury
We next examined whether peripheral nerve injury altered
number of Kv1.2-positive neurons in the injured DRG.
Nerve injury caused by SNL (n = 4 rats/time point), but
not sham surgery (n = 4 rats/time point), time-depen-
dently decreased the number of Kv1.2-positive neurons in
the ipsilateral L5 DRG (Figure 3A-C). The number of
Kv1.2-positive neurons in the ipsilateral L5 DRG was sig-
nificantly decreased by 25.2% on day 3 (p < 0.05), 84.8%
on day 7 (p < 0.01) and by 52.2% on day 14 (p < 0.01) post-in DRG neurons. Double immunohistochemical staining shows that
, 2.45% for IB4 (D–F), 11.11% for P2X3 (G–I), 3.97% for SP (J–L), and
Figure 3 Time-dependent decreases in the number of Kv1.2-positive neurons in the injured DRG after peripheral nerve injury.
Representative Kv1.2 immunohistochemical staining (Top) and statistical summary (Bottom) of the percentage of Kv1.2-positive neurons in the
contralateral (Contra) and ipsilateral (Ipsi) L5 DRGs on days 3 (A), 7 (B), and 14 (C) after L5 spinal nerve ligation (SNL) or sham surgery and on day
7 after axotomy or sham surgery (D). Scale bar: 100 μm. * P < 0.05, ** P < 0.01 compared to the number of Kv1.2-positive neurons on the
contralateral side of sham-operated rats.
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points in the contralateral DRGs of the sham groups
(Figure 3A-3C). These decreases occurred predominantly
in large and medium DRG neurons. As expected, the
number of Kv1.2-positive neurons in the contralateral L5
DRG did not change significantly at any time point post-
SNL (Figure 3A-C). No dramatic changes in number of
Kv1.2-positive neurons were also seen in either the ipsila-
teral or contralateral L4 DRG during the observation
period (data not shown).
To further verify the effect of SNL on the number of
Kv1.2-positive neurons in the injured DRG, we examined
Kv1.2 immunostaining in the ipsilateral L5 DRG on day
7 after sciatic nerve axotomy or sham surgery. As ex-
pected, sham surgery did not significantly change the
number of Kv1.2-psotive neurons in the ipsilateral or
contralateral L5 DRG (Figure 3D). However, as in theSNL model, the number of Kv1.2-positive neurons in the
ipsilateral L5 DRG was reduced by 75.6% (p < 0.01; n = 4
rats) after axotomy compared to that after sham surgery
(n = 4 rats) (Figure 3D).
Over-expressing Kv1.2 in the injured DRG blunted
neuropathic pain without affecting basal nociceptive
responses
Kv1.2 controls neuronal excitability [30]. Peripheral nerve
injury-induced Kv1.2 downregulation might engage in ab-
normal spontaneous activity in the injured DRG neurons
and participate in the mechanisms that underlie neuro-
pathic pain [16]. Thus, rescuing Kv1.2 downregulation in
the injured DRG may affect nerve injury-induced pain
hypersensitivity. To this end, a full-length Kv1.2 cDNA
was cloned into a proviral AAV5 vector to replace EGFP
cDNA. As shown in Figure 4A, cultured HEK-293 cells
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expressed Kv1.2 protein at the expected size. To further
test whether this cloned protein could produce functional
currents, we carried out voltage-clamped recording. As
expected, no voltage-dependent current was detected in
the EGFP vector-transfected cells (data not shown). How-
ever, Kv1.2 vector-transfected cells exhibited voltage-
dependent currents (Figure 4B). These current densities
could be blocked dramatically by a selective Kv1.2 current
inhibitor, maurotoxin [31-33] (Figure 4B and 4C), indica-
ting that the recording currents are Kv1.2-mediated.
To overexpress Kv1.2 RNA in DRG in vivo, we injected
AAV5-Kv1.2 viral particles into the left L5 DRG. The same
amount of AAV5-EGFP viral particles was injected as a
control. Consistent with the previous reports [16,18,19],
the injected rats showed no signs of paresis or other
abnormalities. The injected DRGs, stained with hema-
toxylin/eosin, retained their structural integrity and con-
tained no visible leukocytes (data not shown) indicating
that the immune responses from viral injection were
minimal. Because AAV5 takes 3–4 weeks to become
expressed in in vivo [16,18,19], SNL was carried out 4
weeks after injection. We first compared paw withdrawal
responses to mechanical, cold, or thermal stimuli between
pre- and post-viral injection. There were no significant
changes in paw withdrawal thresholds or latencies on
either hind paw 4 weeks after viral injection compared to
the baseline thresholds or latencies (Figure 5). We then
examined whether over-expressing Kv1.2 RNA in the
injured DRG affected neuropathic pain development. As
expected, SNL produced mechanical, cold, and thermalFigure 4 In vitro expression and current of Kv1.2 in HEK-293 cells tran
Kv1.2 expression at the expected size in HEK-293 cells transfected with full-leng
traces of Kv1.2 current recorded by whole-cell voltage patch clamp in HEK-293
of 100 nM maurotoxin (MTX). (C) Current–voltage curves of HEK-293 cells trans
The current density was plotted against each step testing voltage. n = 5 cells.hypersensitivities on the ipsilateral side in the EGFP-
injected group (n = 5 rats; Figure 5A-C). However, hyper-
sensitivity was attenuated in the Kv1.2-injected rats (n = 5
rats; Figure 5A-C). Paw withdrawal threshold to mechan-
ical stimulation and paw withdrawal latencies to cold and
thermal stimuli were higher in the Kv1.2-injected rats than
in the EGFP-injected group from day 3 to day 14 post-
SNL (Figure 5A-C). To further investigate the effect of
over-expressing Kv1.2 RNA on neuropathic pain mainte-
nance, we subjected rats to SNL one week after DRG viral
injection. As shown in Figure 5D-F (n = 5 rats/group),
mechanical, cold, and thermal hypersensitivities com-
pletely developed in both the Kv1.2-injected and EGFP-
injected rats from day 3 to day 14 post-SNL (Figure 5D-F).
These hypersensitivities were attenuated on days 21, 28,
and 35 post-SNL in the Kv1.2-injected rats compared to
the EGFP-injected rats (Figure 5D-F). Neither AAV5-
Kv1.2 nor AAV5-EGFP affected paw withdrawal threshold
or latency on the contralateral side in the develop-
ment and maintenance of SNL-induced neuropathic pain
(Figure 5).
Over-expressing Kv1.2 in the DRG did not alter capsaicin-
induced acute pain
To further examine whether over-expressing Kv1.2 in the
DRG altered acute pain, we subjected rats to capsaicin
and observed capsaicin-induced acute nociceptive pain
characterized by licking and/or lifting of the injected hind
paw (n = 5 rats/group). Consistent with the previous re-
ports [24], the nocifensive response evoked by capsaicin
occurred predominantly during the first 5-min observationsfected with Kv1.2 vector. (A) Representative Western blot showing
th Kv1.2 vector. β-actin was used as a loading control. (B) Representative
cells transfected with full-length Kv1.2 vector before or after bath perfusion
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Figure 5 Overexpressing Kv1.2 in the injured DRG mitigates neuropathic pain. Kv1.2 was delivered into the injured DRG through
microinjection of AAV5-Kv1.2. AAV5-EGFP was used as a control. (A-C) Behavioral tests show the effect of overexpressing Kv1.2 on the development of
spinal nerve ligation (SNL)-induced pain hypersensitivities. Ipsilateral and contralateral paw withdrawal responses to mechanical (A), cold (B), and thermal
(C) stimuli at the times shown before and after SNL. n = 5/group. *P< 0.05, **P< 0.01 vs. the ipsilateral side of the AAV5-EGFP-treated group at the
corresponding time point. (D-F) Behavioral tests show the effect of overexpressing Kv1.2 on the maintenance of SNL-induced pain hypersensitivities.
Ipsilateral and contralateral paw withdrawal responses to mechanical (D), cold (E), and thermal (F) stimuli at the times shown before and after SNL.
n = 5/group. *P< 0.05, **P< 0.01 vs. the ipsilateral side of the AAV5-EGFP-treated group at the corresponding time point.
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http://www.molecularpain.com/content/10/1/8period. We found that capsaicin-induced the paw licking/
lifting response in this period from the Kv1.2-injected
group was similar to that from the EGFP-injected group
(Figure 6A). We further tested paw withdrawal responses
to mechanical, thermal, and cold stimuli 30 min after cap-
saicin injection. No significant differences were observed
between the EGFP-injected and Kv1.2-injected groups
(Figure 6B and 6C).
Over-expressing Kv1.2 RNA in the DRG did not affect
locomotor functions
We also determined whether over-expressing Kv1.2 RNA
influenced locomotor function of experimental animals.
As shown in Table 1, neither AAV5-Kv1.2 nor AAV5-
EGFP produced any effect on locomotor functions in-
cluding placing, grasping and righting reflexes in naïve
(n = 5), EGFP-treated (n = 5), and Kv1.2-treated (n = 5)
rats. Convulsions and hypermobility were not observed in
any of the treated animals. In addition, we did not observe
any significant difference in general behaviors, includingthe gait and spontaneous activity, between naïve rats and
the AAV5-treated groups.
Over-expressing Kv1.2 RNA in the DRG attenuated
SNL-induced DRG Kv1.2 antisense (AS) RNA upregulation
We recently reported that Kv1.2 AS RNA as a trigger con-
tributes to neuropathic pain development and mainten-
ance by specifically silencing Kv1.2 mRNA in the DRG
[16]. Therefore, we finally defined whether the antino-
ciceptive effect of DRG Kv1.2 RNA overexpression was
attributed to the expressional change of DRG Kv1.2 AS
RNA. Consistent with our previous work [16], SNL down-
regulated Kv1.2 mRNA and protein and upregulated Kv1.2
AS RNA in the injured DRG 14 days after SNL in the
EGFP-injected group (n = 5 rats; Figure 7A and B). Over-
expressing Kv1.2 RNA in the injured DRG not only res-
cued the SNL-induced decrease in DRG Kv1.2 mRNA and
protein but also blocked the SNL-evoked increase in DRG
Kv1.2 AS RNA in the Kv1.2-injected group (Figure 7A and
B). In sham rats, over-expressing Kv1.2 RNA in the DRG
Figure 6 Overexpressing Kv1.2 in the DRG does not alter capsaicin-induced acute nociceptive pain. (A) The duration of capsaicin-induced
paw licking/lifting was recorded for 5 minutes after capsaicin injection in the AAV5-EGFP-injected and AAV5-Kv1.2-injected groups. n = 5/group. (B-D) Paw
withdrawal responses of AAV5-EGFP-injected and AAV5-Kv1.2-injected rats to mechanical (B), heat (C), and cold (D) stimuli on the ipsilateral side prior
to viral injection (baseline), before capsaicin injection (Pre-Cap; 5 weeks after viral injection), and 30 minutes after capsaicin injection
(Post-Cap). n = 5/group.
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http://www.molecularpain.com/content/10/1/8also inhibited basal DRG Kv1.2 AS RNA expression in
addition to increasing basal DRG Kv1.2 mRNA and pro-
tein (Figure 7A and C). The levels of Kv1.4 mRNA and
protein were unaffected by the over-expression of DRG
Kv1.2 RNA in either SNL or sham rats compared to the
corresponding EGFP-injected group (Figure 7A-C).
Discussion
Three major findings arise from the present study. First,
Kv1.2 expressed in a majority of the large and medium
DRG neurons is time-dependently downregulated in the
injured DRG following peripheral nerve injury induced
by L5 SNL and sciatic nerve axotomy. Second, rescuing
this downregulation by over-expressing DRG Kv1.2 RNA
blocked the development and maintenance of SNL-
induced neuropathic pain. Finally, over-expressing DRG
Kv1.2 did not affect basal acute pain, capsaicin-inducedTable 1 Mean (± SDM) changes in locomotor test
Groups Placing Grasping Righting
EGFP in naive 5 (0) 5 (0) 5 (0)
Kv1.2 in naive 5 (0) 5 (0) 5 (0)
EGFP in sham 5 (0) 5 (0) 5 (0)
Kv1.2 in sham 5 (0) 5 (0) 5 (0)
EGFP in SNL 5 (0) 5 (0) 5 (0)
Kv1.2 in SNL 5 (0) 5 (0) 5 (0)
N = 5/group, 5 trials.acute pain, and locomotor functions. These findings sug-
gest that the DRG Kv1.2 channel may be a novel poten-
tial target for treating neuropathic pain.
Normal DRG expresses several Kv1 alpha subunits at
various levels of basal expression. RT-PCR analysis
showed that Kv1.1 and Kv1.2 mRNA was highly abundant,
whereas Kv1.3, Kv1.4, Kv1.5, and Kv1.6 mRNA was
present at lower levels [12]. Immunohistochemistry fur-
ther revealed that Kv1.1, Kv1.2, and Kv1.4 protein was
detected highly in DRG neurons [14]. In contrast, Kv1.3,
Kv1.5, and Kv1.6 protein expression was very low or
undetectable in the DRG [14]. Consistent with these fin-
dings, we found that approximately 70% of DRG neurons
expressed Kv1.2 protein in neuron profiles. These findings
suggest that Kv1.2, Kv1.1, and Kv1.4 are key subunits in
formation of heteromeric Kv channels in DRG neurons.
Kv1 alpha subunits are present in distinct classes of
DRG neurons. An early study reported that Kv1.1 and
Kv1.2 are expressed in small-sized DRG neurons [13].
This finding was not confirmed in a subsequent study that
showed Kv1.2 and Kv1.1 to be expressed predominantly in
medium- and large-sized DRG neurons [14]. We used
specific cytochemical markers and the measurement of
neuronal cell body area to further characterize Kv1.2 ex-
pression in functional classes of DRG neurons. In neuron
profiles, approximately 72% of Kv1.2-positive neurons
were large, 19% were medium, and 9% were small. Con-
sistently, we found that most (80.3%) Kv1.2 co-localized
Figure 7 Overexpressing Kv1.2 rescues SNL-induced Kv1.2 downregulation and blocks SNL-induced Kv1.2 AS RNA upregulation in the
injured DRG. (A) Quantitative RT-PCR shows Kv1.2 AS RNA, Kv1.2 mRNA, and Kv1.4 mRNA expression in the ipsilateral and contralateral L5 DRGs on
day 14 after spinal nerve ligation (SNL) or sham surgery in the AAV5-EGFP-injected and AAV5-Kv1.2-injected groups. n = 12 rats/group. **P < 0.01 vs.
the corresponding AAV5-EGFP-injected group after sham surgery; ##P < 0.01 vs. the corresponding AAV5-EGFP-injected group after SNL. (B) Western
blot analysis shows Kv1.2 and Kv1.4 protein expression in the ipsilateral (Ipsi) and contralateral (Con) L5 DRGs on day 14 after SNL in the AAV5-EGFP-
injected and AAV5-Kv1.2-injected groups. n = 8 rats/group. **P < 0.01 vs. the contralateral side of the AAV5-EGFP-injected group; #P < 0.05 vs. the
ipsilateral side of the AAV5-EGFP-injected group. (C) Western blot analysis shows Kv1.2 and Kv1.4 protein expression in the ipsilateral and contralateral
L5 DRGs on day 14 after sham surgery in the AAV5-EGFP-injected and AAV5-Kv1.2-injected groups. n = 8 rats/group. **P < 0.01 vs. the contralateral side
of the AAV5-EGFP-injected group.
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http://www.molecularpain.com/content/10/1/8with NF200, a marker for large, myelinated afferents,
and some co-localized with P2X3 (11.11%) and CGRP
(10.7%), markers of small nociceptive cells. Unexpec-
tedly, few Kv1.2-positive neurons co-expressed two other
markers of small nociceptive cells, IB4 (2.45%) and SP
(3.97%). It is unclear why Kv1.2 showed different levels of
co-localization with distinct nociceptive markers, but the
observation may be related to different subpopulation dis-
tribution of these markers in rat DRG. CGRP and P2X3
are expressed not only in small DRG neurons but also in
medium and/or large DRG neurons, whereas SP and IB4
are expressed exclusively in small DRG neurons [34-36].
In addition, CGRP is co-expressed with P2X3, but not
with IB4, in some DRG neurons [37]. Unique subpopula-
tion distribution of Kv1.2 in DRG suggests a functional
consequence of its down-regulation on pain-associated
behaviors following peripheral nerve injury.
Nerve injury-induced Kv1.2 downregulation in the in-
jured DRG may participate in neuropathic pain develop-
ment and maintenance. Data from the present study and
those of others [12-16,38,39] showed a time-dependent
decrease in expression of Kv1.2 mRNA and protein in the
injured DRG neurons following peripheral nerve injury.
This decrease occurred predominantly in large and
medium DRG neurons. We recently demonstrated that
DRG Kv1.2 reduction in the large and medium DRG
neurons decreased total voltage-gated potassium current,depolarized the resting membrane potential, decreased
current threshold for activation of action potentials, in-
creased the number of action potentials in these DRG
neurons, and produced neuropathic pain symptoms [16].
Blocking SNL-induced reduction of Kv1.2 expression in
the injured DRG attenuated neuropathic pain during de-
velopment and maintenance periods [16]. The evidence
indicates that DRG Kv1.2 is a key player in neuropathic
pain genesis and may be a potential target for preventing
and/or treating neuropathic pain. Consistent with this
speculation, the present study demonstrated that rescuing
Kv1.2 expression in the injured DRG diminished the in-
duction and maintenance of SNL-induced mechanical,
cold, and thermal pain hypersensitivities. These behavioral
effects may be attributed to direct compensation of SNL-
induced reduction of Kv1.2 protein and inhibition of SNL-
induced upregulation of Kv1.2 AS RNA in the injured
DRG. The latter may be related to the extensive overlap of
complimentary regions between Kv1.2 mRNA and Kv1.2
AS RNA [16]. Given that the nerve injury-induced in-
crease in spontaneous ectopic activity in the injured mye-
linated afferents [40-42] is believed to play a leading role
in the genesis of neuropathic pain [1,43], rescuing Kv1.2
downregulation may maintain normal resting membrane
potential and reduce abnormal ectopic activity in the
injured DRG neurons. This effect may decrease primary
afferent transmitter release and result in attenuation of
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induced pain hypersensitivity. Interestingly, rescuing DRG
Kv1.2 expression does not alter acute pain, which is sup-
ported by the observation that the altered DRG Kv1.2
expression did not change the threshold of action poten-
tial [16]. Therefore, the strategy of rescuing DRG Kv1.2
expression may be a novel treatment for neuropathic pain.
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